Determination of intracellular efficacies of azithromycin against Leishmania major infection in human neutrophils in vitro

Cell Biochemistry and Function

Volumn 21, Issue 1, 2003, Pages 93-96

  Tanyuksel, Mehmet ^a   Bas, A Levent ^b   Araz, Engin ^a   Aybay, Cemalettin ^c  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b SELCUK UNIVERSITY   (Turkey)

^c GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Azithromycin; Intracellular; Leishmania major; Neutrophil

Indexed keywords

ACRIDINE ORANGE; AZITHROMYCIN;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIPROTOZOAL ACTIVITY; ARTICLE; BINDING AFFINITY; CELL KILLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; FEMALE; FLUORESCENCE MICROSCOPY; LEISHMANIA MAJOR; MOUSE; NEUTROPHIL; NONHUMAN; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROMASTIGOTE; SKIN LEISHMANIASIS;

ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CELLS, CULTURED; FEMALE; HUMANS; LEISHMANIA MAJOR; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; NEUTROPHILS; PHAGOCYTOSIS;

LEISHMANIA MAJOR;

EID: 0037372568     PISSN: 02636484     EISSN: None     Source Type: Journal    
DOI: 10.1002/cbf.1004     Document Type: Article

References (21)

1. Chance ML. New developments in the chemotherapy of leishmaniosis. Ann Trop Med Parasitol 1995; 89: 37-43.
2. Retsema J, Girard A, Schelkly W, et al. Spectrum and mode of action of azitromycin. (CP-62, 993), a new 15-membered-ring macrolide with improved potency against gram negative organisms. Antimicrob Ag Chemother 1987; 31: 1939-1947.
3. Lode H. The pharmacokinetics of azitromycin and their clinical significance. Eur J Clin Microbiol Infect Dis 1991; 10: 807-812.
4. Glaude RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62, 993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Ag Chemother 1989; 3: 277-282.
5. Morsy TA. Cutaneous leishmaniasis in Egypt (review and comment). J Egypt Soc Parasitol 1996; 26: 105-130.
6. Sacks DL, Perkins PV. Identification of an ineffective stage of Leishmania promastigote. Science 1984; 223: 1417-1419.
7. Adinolfi LE, Bonventre PF. Enhanced phagocytosis, killing, and serum sensitivity of Escherichia coli and Staphylococcus aureus treated with sub-MICs of imipenem. Antimicrob Ag Chemother 1988; 32: 1012-1018.
8. Das PK, Murray GJ, Barranger JA. Studies on the turnover of glucocerebrosidase in cultural rat peritoneal macrophages and normal human firoblasts. Eur J Biochem 1986; 154: 445-450.
9. Paulsen P, Simon C, Peters O, Hedderich J, Heim P. Influence of azithromycin and other macrolides on the intracellular killing of Staphylococcus aureus by human polymorphonuclear leucocytes of healthy donors and patient with Chiadk-Higashi syndrome. Chemotherapy 1992; 38: 185-190,
10. Bertalanffy FD, Hagy KP. Fluorescence microscopy and photography with acridine orange. Med Radiograph Photograph 1962; 38: 82-91.
11. Linther PJ, Eberhart RJ. Effect of bovine mammary secretion during early nonlactating period and antibiotics on polymorphonuclear neutrophil function and morphology. Am J Vet Res 1990; 51: 524-532.
12. Linther PJ, Eberhart RJ. Effect of antibiotics on phagocyte recruitment, function and morphology in the bovine mammary gland during the early nonlactating period. Am J Vet Res 1990; 51: 533-542.
13. Guy RA, Belosevic M. Comparison of receptors required for entry of Leishmania major amastigotes into macrophages. Infect Immun 1993; 61: 1553-1558.
14. Wilson ME, Anderson KA, Britigan BE. Response of Leishmania chagasi promastigotes to oxidant stress. Infect Immun 1994; 62: 5133-5141.
15. Pearson RD, Sousa AQ. Leishmania species: visceral (Kala-Azar), cutaneous, and mucosal leishmaniasis. In Principle and Practice of Infectious Diseases (4th edn), Mandell GL, Bennett JE, Dolin R (eds). Churchill Livingston Inc: New York, 1995; 2428-2442.
16. Schlossberg D. Azithromycin and clarithromycin. Med Clin North Am 1995; 79: 803-815.
17. Rosenblatt JE. Antiparasitic agents. Mayo Clin Proc 1992; 67: 276-287.
18. Derouin F. New pathogens and mode of action of azithromycin: Toxoplasma gondii. Pathol Biol-Paris 1995; 43: 561-564.
19. Ravdin JI, Skilogiannis J. In vitro susceptibilites of Entamoeba histolytica to azithromycin, CP-63, 956, erythromycin and metranidazol. Antimicrob Ag Chemother 1989; 33: 960-962.
20. Crouch AA, Seow WK, Whitman LM, Thong YH. Sensitivity in vitro of Giardia intestinalis to diadic combinations of azithromycin, doxycycline, mefloquine, tinidazol, and furazolidone. Trans R Soc Trop Med Hyg 1990; 84: 246-248.
21. Williams JD. Spectrum of activity of azithromycin. Eur J Clin Microbiol Infect Dis 1991; 10: 813-820.